---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-26-014504"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2026-11-17T21:30:32+00:00"
generated_at: "2026-11-17T21:33:14.224610+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.62
calibrated_materiality_score: 0.62
confidence: "high"
source: SEC EDGAR
---

# Alzamend pauses AL001 bipolar trial after FDA rejects enrollment-criteria change; MGH terminates BD SOW

## Summary
- FDA wrote on Oct 15, 2026 that the AL001 bipolar trial design did not appear adequate and well-controlled enough to support an NDA.
- Alzamend paused the BD Clinical Trial on Oct 21, 2026 after MGH said co-morbidity exclusions (diabetes, cardiovascular disease, anxiety) hampered enrollment.
- MGH terminated the bipolar statement of work on Nov 11, 2026 and will refund about $25,000 in unused funds; the Healthy SOW is unaffected.
- Company will seek a Type B FDA meeting on a revised plan expected to drop Phase II and move directly to a Phase III efficacy/safety trial in bipolar; feedback targeted by end of Q2 2027.
- Final clinical study report and results for the Healthy Patient Clinical Trial, initiated May 2025 and completed Nov 2025, are expected in December 2026.

## SEC filing metadata
- accession: 0001214659-26-014504
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2026-11-17T21:30:32+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.62
- calibrated_materiality_score: 0.62
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/0001214659-26-014504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465926014504/o11172648k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-26-014504
- JSON: https://secwatch.observer/filing/0001214659-26-014504.json
- Plain text: https://secwatch.observer/filing/0001214659-26-014504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
